Vanguard Global Advisers’s Damora Therapeutics DMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$405K Buy
19,043
+12,681
+199% +$358K ﹤0.01% 2187
2026
Q2
$165K Buy
6,362
+99
+2% +$2.4K ﹤0.01% 2571
2026
Q1
$162K Buy
+6,263
New +$161K ﹤0.01% 2536

Other funds holding DMRA

Vanguard Global Advisers's DMRA Position: Q3 2026 in Review

Vanguard Global Advisers increased its Damora Therapeutics (DMRA) stake by 199% in Q3 2026, buying an estimated $358K and bringing the position to 19,043 shares worth $405K. The position accounts for ﹤0.01% of the portfolio, ranked #2187.

Vanguard Global Advisers first reported a position in DMRA in Q1 2026 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

  • Vanguard Global Advisers held 19,043 shares of Damora Therapeutics worth $405K as of Q3 2026.
  • Vanguard Global Advisers bought 12,681 Damora Therapeutics shares in Q3 2026, an estimated $358K.
  • Damora Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2187 holding.
  • Vanguard Global Advisers first reported a position in Damora Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.